Tofacitinib

RED:

NICE TA480 - for treatment of moderate-to-severe active rheumatoid arthritis. (Decision date - November 2017)
NICE TA543 - for the treatment of active psoriatic arthritis after inadequate response to DMARDS (Decision date - November 2018)
NICE TA547 - for moderately to severely active ulcerative colitis. (Decision date - December 2018)
NICE TA735 - for treating juvenile idiopathic arthritis. NHSE commissioned. (Decision date - November 2021)
NICE TA920 - for treating active ankylosing spondylitis. ICB commissioned (Decision date - November 2023)

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)